Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Goodwill (2016 - 2025)

Amicus Therapeutics filings provide 13 years of Goodwill readings, the most recent being $197.8 million for Q4 2025.

  • On a quarterly basis, Goodwill changed 0.0% to $197.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $197.8 million, a 0.0% change, with the full-year FY2025 number at $197.8 million, changed 0.0% from a year prior.
  • Goodwill hit $197.8 million in Q4 2025 for Amicus Therapeutics, roughly flat from $197.8 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $197.8 million in Q4 2021 to a low of $197.8 million in Q1 2021.
  • Median Goodwill over the past 5 years was $197.8 million (2021), compared with a mean of $197.8 million.
  • Biggest five-year swings in Goodwill: changed 0.0% in 2021 and later decreased 0.0% in 2022.
  • Amicus Therapeutics' Goodwill stood at $197.8 million in 2021, then dropped by 0.0% to $197.8 million in 2022, then changed by 0.0% to $197.8 million in 2023, then changed by 0.0% to $197.8 million in 2024, then changed by 0.0% to $197.8 million in 2025.
  • The last three reported values for Goodwill were $197.8 million (Q4 2025), $197.8 million (Q3 2025), and $197.8 million (Q2 2025) per Business Quant data.